Identification of endogenous 1-aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation.

Hua MiaoGang CaoXia-Qing WuYuan-Yuan ChenDan-Qian ChenLin ChenNosratola D VaziriYa-Long FengWei SuYi GaoShougang ZhuangXiao-Yong YuLi ZhangYan GuoYing-Yong Zhao

Published in: British journal of pharmacology (2020)

We uncovered that endogenous AP is a novel mediator of CKD progression via AhR activation; thus, AhR might serve as a promising target for CKD treatment.

Keyphrases

chronic kidney disease
end stage renal disease
multiple sclerosis
transcription factor